Understanding SUBSYS and Its Manufacturer: A Pharmaceutical Overview
As an increasing number of visitors to our webpage have been inquiring about the status of "SUBSYS" stock, we believe it is important to provide a clear and comprehensive overview of the product, its manufacturer, and its current position in the market.
What is SUBSYS?
SUBSYS is the brand name for a sublingual fentanyl spray developed by Insys Therapeutics. It is designed for the management of breakthrough pain in adult cancer patients who are already tolerant to a regime of around-the-clock opioid therapy for their underlying persistent cancer pain. Fentanyl, the active ingredient in SUBSYS, is a potent synthetic opioid that is significantly stronger than morphine.
The Manufacturer: Insys Therapeutics
The maker of SUBSYS, Insys Therapeutics, was a pharmaceutical company known for developing and commercializing innovative drugs and drug delivery systems. Founded in 1990 and headquartered in Chandler, Arizona, Insys Therapeutics sought to address the clinical shortcomings of existing therapeutic approaches.
Controversy and Legal Challenges
It is critical to acknowledge that Insys Therapeutics has been embroiled in significant controversy. The company faced serious legal challenges regarding its marketing practices, particularly with the promotion of SUBSYS. Allegations of contributing to the opioid epidemic through aggressive and inappropriate marketing tactics led to lawsuits and heightened scrutiny from regulatory bodies.
Bankruptcy and Delisting
As a consequence of these legal difficulties, Insys Therapeutics filed for bankruptcy protection in 2019. This action followed the financial and reputational damage resulting from the lawsuits and settlements the company faced related to the marketing of SUBSYS.
Current Trading Status
In light of these developments, it is important for current and potential investors to understand that Insys Therapeutics is not currently publicly traded. After filing for bankruptcy, the company's stocks were delisted from any public stock exchange, meaning that there is no market for trading Insys Therapeutics stock at this time.
Conclusion
While the inquiry into "SUBSYS" stock is understandable, given the historical presence of Insys Therapeutics in the public market, it is imperative to be informed that the stock is no longer an option for trading. We recommend that those interested in pharmaceutical investments focus on other entities that are actively traded and offer transparency and stability in their operations.
For the most recent information and guidance, investors should always consult with financial advisors and conduct due diligence when considering any potential investment, especially in the complex and heavily regulated pharmaceutical sector.